Michaël Lukens

Michaël Lukens is an active researcher specializing in hematology and immunology with significant contributions to transfusion medicine, thrombosis research, and clinical trials. His work spans multiple high-impact publications in journals including Nature Communications, British Journal of Haematology, and Thrombosis Research.

His research focuses on transfusion protocols, antibody-mediated complications, and anticoagulant dosing strategies. Key themes include Rhesus antibody prevention in pregnancy, nadroparin pharmacokinetics in renal impairment, and management of rare immunological disorders like CHAPLE syndrome. His fingerprint analysis reveals deep expertise in cytotoxic T-cell responses, anti-Xa monitoring, and thromboprophylaxis.

Lukens participates in major collaborative studies including the CoV-Early and COnV-ert COVID-19 convalescent plasma trials, WISE national transfusion observational study, and research on Human Respiratory Syncytial Virus. His work contributes to UN Sustainable Development Goals through advancements in blood safety and maternal health.

He maintains active external collaborations across multiple countries, particularly in European clinical research networks. Current projects address critical gaps in transfusion waste reduction, personalized anticoagulation, and management of complex immunohematological conditions.